Fabrizio De Benedetti

Fabrizio De Benedetti's AcademicInfluence.com Rankings

Physics

#7101

World Rank

#9110

Historical Rank

physics Degrees

Download Badge

Physics

Fabrizio De Benedetti's Degrees

PhD Physics University of Milan
Masters Physics University of Milan
Bachelors Physics University of Milan

Why Is Fabrizio De Benedetti Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Fabrizio De Benedetti's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis. (2012) (702)
Juvenile Idiopathic Arthritis (2000) (697)
Interleukin 6 Is Required for the Development of Collagen-induced Arthritis (1998) (641)
On the Alert for Cytokine Storm: Immunopathology in COVID‐19 (2020) (562)
Interleukin 6 causes growth impairment in transgenic mice through a decrease in insulin-like growth factor-I. A model for stunted growth in children with chronic inflammation. (1997) (511)
2016 Classification Criteria for Macrophage Activation Syndrome Complicating Systemic Juvenile Idiopathic Arthritis: A European League Against Rheumatism/American College of Rheumatology/Paediatric Rheumatology International Trials Organisation Collaborative Initiative (2016) (486)
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2010 (2011) (464)
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2011 (2006) (464)
Correlation of serum interleukin-6 levels with joint involvement and thrombocytosis in systemic juvenile rheumatoid arthritis. (1991) (344)
Impaired skeletal development in interleukin-6-transgenic mice: a model for the impact of chronic inflammation on the growing skeletal system. (2006) (282)
Translating IL-6 biology into effective treatments (2020) (262)
Macrophage activation syndrome in the era of biologic therapy (2016) (258)
Canakinumab for the Treatment of Autoinflammatory Recurrent Fever Syndromes (2018) (246)
Mutation screening of the macrophage migration inhibitory factor gene: positive association of a functional polymorphism of macrophage migration inhibitory factor with juvenile idiopathic arthritis. (2002) (240)
Efficacy and safety of tocilizumab in patients with polyarticular-course juvenile idiopathic arthritis: results from a phase 3, randomised, double-blind withdrawal trial (2014) (238)
2016 Classification Criteria for Macrophage Activation Syndrome Complicating Systemic Juvenile Idiopathic Arthritis (2016) (236)
Serum soluble interleukin 6 (IL-6) receptor and IL-6/soluble IL-6 receptor complex in systemic juvenile rheumatoid arthritis. (1994) (228)
Emapalumab in Children with Primary Hemophagocytic Lymphohistiocytosis. (2020) (226)
Classification criteria for autoinflammatory recurrent fevers (2019) (216)
Treating juvenile idiopathic arthritis to target: recommendations of an international task force (2018) (209)
Mutations in the perforin gene can be linked to macrophage activation syndrome in patients with systemic onset juvenile idiopathic arthritis. (2010) (202)
Functional and prognostic relevance of the -173 polymorphism of the macrophage migration inhibitory factor gene in systemic-onset juvenile idiopathic arthritis. (2003) (196)
Inhibition of Natural Killer Cell Cytotoxicity by Interleukin‐6: Implications for the Pathogenesis of Macrophage Activation Syndrome (2015) (189)
Elevated circulating levels of interferon-γ and interferon-γ-induced chemokines characterise patients with macrophage activation syndrome complicating systemic juvenile idiopathic arthritis (2016) (187)
Drug Retention Rate and Predictive Factors of Drug Survival for Interleukin-1 Inhibitors in Systemic Juvenile Idiopathic Arthritis (2019) (185)
Defective iron supply for erythropoiesis and adequate endogenous erythropoietin production in the anemia associated with systemic-onset juvenile chronic arthritis. (1996) (184)
Effect of IL-6 on IGF binding protein-3: a study in IL-6 transgenic mice and in patients with systemic juvenile idiopathic arthritis. (2001) (165)
NGF and Its Receptors in the Regulation of Inflammatory Response (2017) (157)
Is systemic juvenile rheumatoid arthritis an interleukin 6 mediated disease? (1998) (156)
An International registry on Autoinflammatory diseases: the Eurofever experience (2012) (151)
Macrophage activation syndrome in systemic juvenile rheumatoid arthritis successfully treated with cyclosporine. (1996) (150)
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2012 (2013) (145)
Cisternal CSF levels of cytokines after subarachnoid hemorrhage. (1998) (132)
A functional promoter haplotype of macrophage migration inhibitory factor is linked and associated with juvenile idiopathic arthritis. (2004) (126)
Familial Mediterranean fever mutations lift the obligatory requirement for microtubules in Pyrin inflammasome activation (2016) (125)
Mechanisms Inducing Low Bone Density in Duchenne Muscular Dystrophy in Mice and Humans (2011) (124)
Macrophage Activation Syndrome: different mechanisms leading to a one clinical syndrome (2017) (118)
A novel disorder involving dyshematopoiesis, inflammation, and HLH due to aberrant CDC42 function (2019) (104)
Abnormal production of the tumor necrosis factor inhibitor etanercept and clinical efficacy of tumor in a patient with PAPA syndrome (2004) (103)
Interleukin-1β and Interleukin-6 in Arthritis Animal Models: Roles in the Early Phase of Transition from Acute to Chronic Inflammation and Relevance for Human Rheumatoid Arthritis (2010) (103)
Emergent high fatality lung disease in systemic juvenile arthritis (2019) (97)
Induction of transforming growth factor-beta 1 (TGF-beta 1), receptor expression and TGF-beta 1 protein production in retinoic acid-treated HL-60 cells: possible TGF-beta 1-mediated autocrine inhibition. (1991) (97)
Amplification of the response to Toll-like receptor ligands by prolonged exposure to interleukin-6 in mice: implication for the pathogenesis of macrophage activation syndrome. (2012) (96)
c-Src and IL-6 inhibit osteoblast differentiation and integrate IGFBP5 signalling (2012) (95)
Effect of Biologic Therapy on Clinical and Laboratory Features of Macrophage Activation Syndrome Associated With Systemic Juvenile Idiopathic Arthritis (2018) (95)
Nerve Growth Factor Downregulates Inflammatory Response in Human Monocytes through TrkA (2014) (92)
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2009 (2009) (87)
Marked and sustained improvement two years after autologous stem cell transplantation in a girl with systemic sclerosis. (1999) (85)
Performance of a component‐based allergen‐microarray in the diagnosis of cow's milk and hen's egg allergy (2010) (83)
Macrophage migration inhibitory factor in patients with juvenile idiopathic arthritis. (2002) (78)
Differences in synovial fluid cytokine levels between juvenile and adult rheumatoid arthritis. (1997) (78)
A Snapshot on the On-Label and Off-Label Use of the Interleukin-1 Inhibitors in Italy among Rheumatologists and Pediatric Rheumatologists: A Nationwide Multi-Center Retrospective Observational Study (2016) (75)
Low Serum Levels of Mannose Binding Lectin Are a Risk Factor for Neonatal Sepsis (2007) (72)
Serum interleukin-6 levels and joint involvement in polyarticular and pauciarticular juvenile chronic arthritis. (1992) (70)
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2008 (2008) (70)
Low-Dose Radiotherapy Reverses Tumor Immune Desertification and Resistance to Immunotherapy (2021) (69)
Development of the autoinflammatory disease damage index (ADDI) (2016) (67)
Expert consensus on dynamics of laboratory tests for diagnosis of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis (2016) (66)
A Novel Targeted Approach to the Treatment of Hemophagocytic Lymphohistiocytosis (HLH) with an Anti-Interferon Gamma (IFNγ) Monoclonal Antibody (mAb), NI-0501: First Results from a Pilot Phase 2 Study in Children with Primary HLH (2015) (66)
Kawasaki disease: guidelines of the Italian Society of Pediatrics, part I - definition, epidemiology, etiopathogenesis, clinical expression and management of the acute phase (2018) (65)
A Heterozygous RAB27A Mutation Associated with Delayed Cytolytic Granule Polarization and Hemophagocytic Lymphohistiocytosis (2016) (65)
Catch‐Up Growth During Tocilizumab Therapy for Systemic Juvenile Idiopathic Arthritis: Results From a Phase III Trial (2015) (65)
Pharmacovigilance in juvenile idiopathic arthritis patients treated with biologic or synthetic drugs: combined data of more than 15,000 patients from Pharmachild and national registries (2018) (65)
Inflammasome activation by cystine crystals: implications for the pathogenesis of cystinosis. (2014) (65)
Anakinra in children and adults with Still’s disease (2019) (64)
Neutralization of IFN‐&ggr; reverts clinical and laboratory features in a mouse model of macrophage activation syndrome (2017) (64)
An Inflammatory Profile Correlates With Decreased Frequency of Cytotoxic Cells in Coronavirus Disease 2019 (2020) (64)
Functional and Morphological Improvement of Dystrophic Muscle by Interleukin 6 Receptor Blockade (2015) (63)
Proinflammatory responses to self HLA epitopes are triggered by molecular mimicry to Epstein-Barr virus proteins in oligoarticular juvenile idiopathic arthritis. (2002) (63)
Safety profile of the interleukin-1 inhibitors anakinra and canakinumab in real-life clinical practice: a nationwide multicenter retrospective observational study (2018) (63)
Elevated circulating interleukin-7 levels in patients with systemic juvenile rheumatoid arthritis. (1995) (61)
Mechanistic associations of a mild phenotype of immunodysregulation, polyendocrinopathy, enteropathy, x-linked syndrome. (2006) (61)
Targeting the interleukin-6 receptor: a new treatment for systemic juvenile idiopathic arthritis? (2005) (60)
Deregulation of the IL-1β axis in chronic recurrent multifocal osteomyelitis (2014) (60)
Circulating levels of interleukin-6, interleukin-8, and tumor necrosis factor-alpha in children with autoimmune hepatitis. (1995) (60)
Immune responses to the Escherichia coli dnaJ heat shock protein in juvenile rheumatoid arthritis and their correlation with disease activity. (1994) (59)
Reaching the Threshold: A Multilayer Pathogenesis of Macrophage Activation Syndrome (2013) (58)
Cytokines in juvenile rheumatoid arthritis. (1997) (57)
Abnormal regulation of interleukin 6 in systemic juvenile idiopathic arthritis. (2001) (57)
Interleukin 8 and monocyte chemoattractant protein-1 in patients with juvenile rheumatoid arthritis. Relation to onset types, disease activity, and synovial fluid leukocytes. (1999) (55)
Self epitopes shared between human skeletal myosin and Streptococcus pyogenes M5 protein are targets of immune responses in active juvenile dermatomyositis. (2002) (55)
IL-6 Amplifies TLR Mediated Cytokine and Chemokine Production: Implications for the Pathogenesis of Rheumatic Inflammatory Diseases (2014) (54)
Role of Interleukin-6 in Growth Failure: An Animal Model (2002) (54)
Abnormal production of tumor necrosis factor (TNF) -- alpha and clinical efficacy of the TNF inhibitor etanercept in a patient with PAPA syndrome [corrected]. (2004) (54)
Circulating levels of interleukin 1 beta and of interleukin 1 receptor antagonist in systemic juvenile chronic arthritis. (1995) (54)
Synergy between transforming growth factor-beta and tumor necrosis factor-alpha in the induction of monocytic differentiation of human leukemic cell lines (1990) (52)
Association of Serum Interleukin-8 Levels with the Degree of Fibrosis in Infants with Chronic Liver Disease (2004) (48)
Increased levels of interleukin-6 exacerbate the dystrophic phenotype in mdx mice (2015) (48)
Anakinra in Systemic Juvenile Idiopathic Arthritis: A Single-center Experience (2015) (47)
In Vivo Neutralization of Human IL-6 (hIL-6) Achieved by Immunization of hIL-6-Transgenic Mice with a hIL-6 Receptor Antagonist1 (2001) (46)
Dramatic efficacy of cyclosporine A in macrophage activation syndrome. (2001) (46)
Hypocomplementemic urticarial vasculitis syndrome with severe systemic manifestations. (1994) (45)
Increased muscle expression of interleukin-17 in Duchenne muscular dystrophy (2012) (43)
Soluble tumour necrosis factor receptor levels reflect coagulation abnormalities in systemic juvenile chronic arthritis. (1997) (43)
Systemic juvenile idiopathic arthritis: New insights into pathogenesis and cytokine directed therapies. (2017) (42)
Muscle Expression of Type I and Type II Interferons Is Increased in Juvenile Dermatomyositis and Related to Clinical and Histologic Features (2019) (42)
Intra-articular corticosteroids versus intra-articular corticosteroids plus methotrexate in oligoarticular juvenile idiopathic arthritis: a multicentre, prospective, randomised, open-label trial (2017) (42)
Secondary thrombocytosis. (1993) (41)
Reversal of nephrotic syndrome due to reactive amyloidosis (AA‐type) after excision of localized Castleman's disease (1994) (41)
Use of a mouse model to identify a blood biomarker for IFNγ activity in pediatric secondary hemophagocytic lymphohistiocytosis (2016) (40)
Correlation of serum neopterin concentrations with disease activity in juvenile dermatomyositis. (1993) (39)
Safety and Efficacy of Etanercept in a Cohort of Patients with Juvenile Idiopathic Arthritis Under 4 Years of Age (2012) (39)
Wolman disease associated with hemophagocytic lymphohistiocytosis: attempts for an explanation (2014) (39)
Stimulating effect of growth hormone on cytokine release in children. (2003) (37)
Role of mannose-binding lectin in nosocomial sepsis in critically ill neonates. (2010) (36)
Association of the macrophage migration inhibitory factor −173*C allele with childhood nephrotic syndrome (2008) (36)
Disease status, reasons for discontinuation and adverse events in 1038 Italian children with juvenile idiopathic arthritis treated with etanercept (2016) (36)
Macrophage migration inhibitory factor (MIF) and oligoarticular juvenile idiopathic arthritis (o-JIA): association of MIF promoter polymorphisms with response to intra-articular glucocorticoids. (2007) (36)
Targeting interleukin-6 in pediatric rheumatic diseases. (2009) (36)
Kawasaki disease: guidelines of Italian Society of Pediatrics, part II - treatment of resistant forms and cardiovascular complications, follow-up, lifestyle and prevention of cardiovascular risks (2018) (35)
Serum level of KL-6 as a marker of interstitial lung disease in patients with juvenile systemic sclerosis. (2004) (35)
Microbiome Analytics of the Gut Microbiota in Patients With Juvenile Idiopathic Arthritis: A Longitudinal Observational Cohort Study (2019) (35)
A Polymorphism in the Macrophage Migration Inhibitory Factor Promoter Is Associated With Bronchopulmonary Dysplasia (2011) (34)
The mature/pro nerve growth factor ratio is decreased in the brain of diabetic rats: Analysis by ELISA methods (2015) (32)
Increased Circulating Levels of Interleukin-6 Affect the Redox Balance in Skeletal Muscle (2019) (32)
Inflammatory events during food protein‐induced enterocolitis syndrome reactions (2017) (30)
Tumor necrosis factor in plasma and peritoneal fluid of women with and without endometriosis. (1993) (30)
Variable Clinical Phenotypes and Relation of Interferon Signature with Disease Activity in ADA2 Deficiency (2019) (29)
Serum cytokine levels in GH-deficient children during substitutive GH therapy. (2005) (28)
OP0204 EMAPALUMAB, AN INTERFERON GAMMA (IFN-Y)-BLOCKING MONOCLONAL ANTIBODY, IN PATIENTS WITH MACROPHAGE ACTIVATION SYNDROME (MAS) COMPLICATING SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS (SJIA) (2019) (28)
Relapsing polychondritis: new therapeutic strategies with biological agents (2010) (28)
Anti-double stranded DNA, anti-histone, and anti-nucleosome IgG reactivities in children with systemic lupus erythematosus. (1994) (28)
Anti-DNA antibodies in the primary antiphospholipid syndrome. (1993) (27)
Blood-based test for diagnosis and functional subtyping of familial Mediterranean fever (2020) (27)
Long-term efficacy and safety of canakinumab in patients with colchicine-resistant familial Mediterranean fever: results from the randomised phase III CLUSTER trial (2020) (26)
Immunoactivation by pidotimod in children with recurrent respiratory infections. (1994) (26)
TOCILIZUMAB IN PATIENTS WITH SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS: EFFICACY DATA FROM THE PLACEBO-CONTROLLED 12-WEEK PART OF THE PHASE III TENDER TRIAL (2011) (25)
An international delphi survey for the definition of the variables for the development of new classification criteria for periodic fever aphtous stomatitis pharingitis cervical adenitis (PFAPA) (2018) (25)
Circulating levels of soluble E-selectin, P-selectin and intercellular adhesion molecule-1 in patients with juvenile idiopathic arthritis. (2000) (24)
Opportunistic infections in immunosuppressed patients with juvenile idiopathic arthritis: analysis by the Pharmachild Safety Adjudication Committee (2020) (23)
The MIF-173G/C polymorphism does not contribute to prednisone poor response in vivo in childhood acute lymphoblastic leukemia (2005) (23)
Anakinra in a Cohort of Children with Chronic Nonbacterial Osteomyelitis (2017) (23)
Identification of HLA-unrestricted CD8+/CD28- cytotoxic T-cell clones specific for leukemic blasts in children with acute leukemia. (1995) (23)
Efficacy and safety of tocilizumab (TCZ) in patients with systemic juvenile idiopathic arthritis (SJIA): tender 52-week data (2011) (22)
Safety and Efficacy of Emapalumab in Pediatric Patients with Primary Hemophagocytic Lymphohistiocytosis (2018) (21)
Dysregulation in B‐cell responses and T follicular helper cell function in ADA2 deficiency patients (2020) (21)
Association Between Mannose-binding Lectin Gene Polymorphisms and Necrotizing Enterocolitis in Preterm Infants (2012) (21)
Mutations of familial hemophagocytic lymphohistiocytosis (FHL) related genes and abnormalities of cytotoxicity function tests in patients with macrophage activation syndrome (MAS) occurring in systemic juvenile idiopathic arthritis (sJIA) (2014) (21)
In silico validation of the Autoinflammatory Disease Damage Index (2018) (21)
Anakinra Drug Retention Rate and Predictive Factors of Long-Term Response in Systemic Juvenile Idiopathic Arthritis and Adult Onset Still Disease (2019) (20)
Switched Memory B Cells Are Increased in Oligoarticular and Polyarticular Juvenile Idiopathic Arthritis and Their Change Over Time Is Related to Response to Tumor Necrosis Factor Inhibitors (2018) (20)
Patients with juvenile idiopathic arthritis become adults: the role of transitional care. (2018) (19)
Interleukin-18 in pediatric rheumatic diseases. (2019) (19)
A56: Macrophage Activation Syndrome in Patients With Systemic Juvenile Idiopathic Arthritis Treated With Tocilizumab (2014) (19)
Rituximab in a childhood-onset idiopathic refractory chronic inflammatory demyelinating polyneuropathy. (2012) (19)
The Impact of Chronic Inflammation on the Growing Skeleton: Lessons from Interleukin-6 Transgenic Mice (2009) (19)
FRI0488 A Phase Iii Pivotal Umbrella Trial of Canakinumab in Patients with Autoinflammatory Periodic Fever Syndromes (Colchicine Resistant FMF, HIDS/MKD and TRAPS) (2016) (19)
Defining colchicine resistance/intolerance in patients with familial Mediterranean fever: a modified-Delphi consensus approach. (2020) (19)
Monocytes and macrophages as biomarkers for the diagnosis of megalencephalic leukoencephalopathy with subcortical cysts (2013) (18)
NLRP2 Regulates Proinflammatory and Antiapoptotic Responses in Proximal Tubular Epithelial Cells (2019) (18)
Targeting interferon-γ in hyperinflammation: opportunities and challenges (2021) (17)
High circulating levels of biologically inactive IL‐6/SIL‐6 receptor complexes in systemic juvenile idiopathic arthritis: evidence for serum factors interfering with the binding to gp130 (2003) (17)
Association of methotrexate treatment with a decrease of double negative (CD4-CD8-) and γ/δ T cell levels in patients with juvenile rheumatoid arthritis (1993) (17)
Mobilization and selection of peripheral blood hematopoietic progenitors in children with systemic sclerosis. (1999) (17)
ProNGF-p75NTR axis plays a proinflammatory role in inflamed joints: a novel pathogenic mechanism in chronic arthritis (2017) (17)
Renal involvement in hypocomplementaemic urticarial vasculitis syndrome: a report of three paediatric cases. (2014) (16)
FRI0328 Efficacy and safety of tocilizumab (TCZ) in patients with systemic juvenile idiopathic arthritis (SJIA): 2-year data from tender, a phase 3 clinical trial (2013) (16)
CD5 positive B lymphocytes in seronegative juvenile arthritis. (1990) (16)
Marked and sustained improvement 2 years after autologous stem cell transplantation in a girl with systemic sclerosis. (1999) (16)
Synergy between Transforming Growth Factor‐β and Tumor Necrosis Factor‐α in the Induction of Monocytic Differentiation of Human Leukemic Cell Lines a (1990) (16)
Inhibition of natural killer (nk) cell cytotoxicity by interleukin-6: implications for the pathogenesis of macrophage activation syndrome (2014) (16)
IFNAR2 Deficiency Causing Dysregulation of NK Cell Functions and Presenting With Hemophagocytic Lymphohistiocytosis (2020) (15)
Haematological involvement associated with a mild autoinflammatory phenotype, in two patients carrying the E250K mutation of PSTPIP1. (2017) (15)
The interferon-gamma pathway is selectively up-regulated in the liver of patients with secondary hemophagocytic lymphohistiocytosis (2019) (14)
Synergistic inhibition of phorbol ester-induced transformation of JB6 cells by transforming growth factor-beta and retinoic acid. (1991) (14)
Serum soluble CD23 levels and CD23 expression on peripheral blood mononuclear cells in juvenile chronic arthritis. (1998) (13)
Chapter 16 – Systemic Juvenile Idiopathic Arthritis (2016) (13)
A novel mutation in the CIAS1/NLRP3 gene associated with an unexpected phenotype of cryopyrin-associated periodic syndromes. (2014) (13)
Lack of temporal association of iridocyclitis with IgG reactivities to core histones and nucleosome subparticles in pauciarticular juvenile chronic arthritis. (1995) (13)
Prediction of inactive disease in juvenile idiopathic arthritis: a multicentre observational cohort study (2018) (13)
Predictors of Flare Following Etanercept Withdrawal in Patients with Rheumatoid Factor–negative Juvenile Idiopathic Arthritis Who Reached Remission while Taking Medication (2018) (13)
Macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis treated with tocilizumab (2014) (13)
Anti interferon-gamma (IFNγ) monoclonal antibody treatment in a patient carrying an NLRC4 mutation and severe hemophagocytic lymphohistiocytosis (2015) (12)
Efficacy and Safety of Tocilizumab for Polyarticular‐Course Juvenile Idiopathic Arthritis in the Open‐Label Two‐Year Extension of a Phase III Trial (2020) (12)
OP0290 EMAPALUMAB (ANTI-INTERFERON-GAMMA MONOCLONAL ANTIBODY) IN PATIENTS WITH MACROPHAGE ACTIVATION SYNDROME (MAS) COMPLICATING SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS (SJIA) (2020) (12)
Induction of Transforming Growth Factor-PI ( TGF-P , ) Receptor Expression and TGF-P , Protein Production in Retinoic Acid-Treated HL-60 Cells : Possible TGF-P ,-Mediated Autocrine Inhibition (2003) (11)
Neutropenia During Tocilizumab Treatment Is Not Associated with Infection Risk in Systemic or Polyarticular-course Juvenile Idiopathic Arthritis (2019) (11)
Caspase-1 levels in biological fluids from patients with multiple sclerosis and from patients with other neurological and non-neurological diseases. (2002) (11)
Early Treatment and IL1RN Single‐Nucleotide Polymorphisms Affect Response to Anakinra in Systemic Juvenile Idiopathic Arthritis (2020) (11)
Hyperinflammation in Two Severe Acute Respiratory Syndrome Coronavirus 2-Infected Adolescents Successfully Treated With the Interleukin-1 Inhibitor Anakinra and Glucocorticoids (2020) (11)
Increased expression of alpha(1,3)-fucosyltransferase-VII and P-selectin binding of synovial fluid T cells in juvenile idiopathic arthritis. (2003) (11)
CD5-positive B cells in type 1 (insulin-dependent) diabetic children. (1993) (11)
Subcutaneous dosing regimens of tocilizumab in children with systemic or polyarticular juvenile idiopathic arthritis (2021) (10)
Treatment journey in rheumatoid arthritis with biosimilars: from better access to good disease control through cost savings and prevention of nocebo effects (2021) (10)
Efficacy and Safety of Canakinumab in Patients with Periodic Fever Syndromes (Colchicine-Resistant FMF, HIDS/MKD and TRAPS): Results from a Phase 3, Pivotal, Umbrella Trial (2017) (10)
Interferon-gamma (IFNy) in macrophage activation syndrome (MAS) associated with systemic juvenile idiopathic arthritis (sJIA). High levels in patients and a role in a murine mas model (2014) (10)
Different responses of PC12 cells to different pro-nerve growth factor protein variants (2019) (9)
Activation-induced cell death and Fas-induced apoptosis in patients with systemic or pauciarticular juvenile idiopathic arthritis. (2001) (9)
A4: Efficacy and Safety of Tocilizumab in Patients With Polyarticular‐Course Juvenile Idiopathic Arthritis: 2‐Year Data From CHERISH (2014) (9)
A14: Neutropenia With Tocilizumab Treatment Is Not Associated With Increased Infection Risk in Patients With Systemic Juvenile Idiopathic Arthritis (2014) (9)
Tocilizumab for systemic juvenile idiopathic arthritis. (2013) (9)
Visceral leishmaniasis as a cause of unexplained fever and cytopenia in systemic lupus erythematosus (2002) (9)
Is fibrodysplasia ossificans progressiva an interleukin-1 driven auto-inflammatory syndrome? (2019) (9)
Development of new classification criteria for macrophage activation syndrome complicating systemic juvenile idiopathic arthritis (2014) (9)
Synergy between transforming growth factor-beta and tumor necrosis factor-alpha in the induction of monocytic differentiation of human leukemic cell lines. (1990) (9)
A6: Tapering and Withdrawal of Tocilizumab in Patients With Systemic Juvenile Idiopathic Arthritis in Inactive Disease: Results From an Alternative Dosing Regimen in the TENDER Study (2014) (8)
Transitional care of young people with juvenile idiopathic arthritis in Italy: results of a Delphi consensus survey. (2019) (8)
Improved Disease Course Associated With Early Initiation of Biologics in Polyarticular Juvenile Idiopathic Arthritis: Trajectory Analysis of a Childhood Arthritis and Rheumatology Research Alliance Consensus Treatment Plans Study (2021) (8)
Growth During Tocilizumab Therapy for Polyarticular-course Juvenile Idiopathic Arthritis: 2-year Data from a Phase III Clinical Trial (2018) (8)
Decreased fibrinolytic activity in juvenile chronic arthritis. (1990) (8)
Toward Accelerated Authorization and Access to New Medicines for Juvenile Idiopathic Arthritis (2019) (8)
Mutations at the C-terminus of CDC42 cause distinct hematopoietic and autoinflammatory disorders. (2022) (8)
An experimental therapy to improve skeletal growth and prevent bone loss in a mouse model overexpressing IL-6 (2014) (8)
Association of methotrexate treatment with a decrease of double negative (CD4-CD8-) and gamma/delta T cell levels in patients with juvenile rheumatoid arthritis. (1993) (7)
Expansion of CD4dimCD8+T cells characterizes macrophage activation syndrome and other secondary HLH. (2022) (7)
Monocytes From Patients With Macrophage Activation Syndrome and Secondary Hemophagocytic Lymphohistiocytosis Are Hyperresponsive to Interferon Gamma (2021) (7)
Definition and validation of serum biomarkers for optimal differentiation of hyperferritinaemic cytokine storm conditions in children: a retrospective cohort study (2021) (7)
A45: Neutropenia With Tocilizumab Treatment Is Not Associated With Increased Infection Risk in Patients With Polyarticular‐Course Juvenile Idiopathic Arthritis (2014) (7)
A patient with stimulator of interferon genes-associated vasculopathy with onset in infancy without skin vasculopathy. (2020) (6)
Proceedings of the 23rd Paediatric Rheumatology European Society Congress: part one (2017) (6)
Calcinosis as the presenting sign of juvenile dermatomyositis in a 14-month-old boy. (1987) (6)
PReS-FINAL-2188: Insulin sensitivity is improved in sjia children with insulin resistance after tocilizumab treatment: results from the tender study (2013) (6)
High levels of interferon-gamma (IFNγ) in macrophage activation syndrome (MAS) and CXCL9 levels as a biomarker for IFNγ production in MAS (2015) (6)
MECHANISMS INDUCING LOW BONE DENSITY IN DUCHENNE MUSCULAR DYSTROPHY (2009) (6)
The activating p.Ser466Arg change in STAT1 causes a peculiar phenotype with features of interferonopathies (2019) (6)
An unusual presentation of purine nucleoside phosphorylase deficiency mimicking systemic juvenile idiopathic arthritis complicated by macrophage activation syndrome (2019) (6)
Tocilizumab may slow radiographic progression in patients with systemic or polyarticular-course juvenile idiopathic arthritis: post hoc radiographic analysis from two randomized controlled trials (2020) (6)
Efficacy and Safety of Tocilizumab in Patients with Systemic Juvenile Idiopathic Arthritis: 2-Year Data From a Phase III Clinical Trial (2011) (6)
Sustained Systemic Levels of IL-6 Impinge Early Muscle Growth and Induce Muscle Atrophy and Wasting in Adulthood (2021) (5)
Macrophage Activation Syndrome (MAS) in Systemic Juvenile Idiopathic Arthritis (sJIA): Treatment with Emapalumab, an Anti-Interferon Gamma (IFNγ) Monoclonal Antibody (2021) (5)
THU0509 Improvement of disease activity in patients with colchicine-resistant FMF, HIDS/MKD and traps assessed by autoinflammatory disease activity index (AIDAI): results from the cluster trial (2017) (5)
Herpes Virus Infections During Treatment With Etanercept in Juvenile Idiopathic Arthritis. (2016) (5)
OP0060 Efficacy and Safety of Tocilizumab in Patients with Polyarticular Juvenile Idiopathic Arthritis: Data from a Phase 3 Trial (2013) (5)
S100A12 as diagnostic tool in the differential diagnosis of sJIA associated MAS vs. hereditary or acquired HLH (2015) (4)
Identification of a Novel Mutation in TNFAIP3 in a Family With Poly-Autoimmunity (2022) (4)
THE EFFICACY OF TOCILIZUMAB IN PATIENTS WITH SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS: 52-WEEK DATA FROM A PHASE 3 CLINICAL TRIAL (2012) (4)
A patient with stimulator of interferon genes-associated vasculopathy with onset in infancy without skin vasculopathy. (2020) (4)
Hemoperfusion with CytoSorb to Manage Multiorgan Dysfunction in the Spectrum of Hemophagocytic Lymphohistiocytosis Syndrome in Critically Ill Children (2021) (4)
Chapter 14 – SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS (2011) (4)
Community poverty level influences time to first pediatric rheumatology appointment in Polyarticular Juvenile Idiopathic Arthritis (2021) (4)
The phenotypic variability of PAPA syndrome: evidence from the Eurofever Registry (2015) (4)
Correction: Rheumatic immune-related adverse events of checkpoint therapy for cancer: case series of a new nosological entity (2017) (4)
OP0217 Adjudication of Infections in The Pharmacovigilance in Juvenile Idiopathic Arthritis Patients (Pharmachild) Treated with Biologic Agents and/or Methotrexate (2016) (4)
Genetic Phenotypes Impacting Efficacy and Safety of Canakinumab in Patients with Colchicine-Resistant FMF, TRAPS and Hids/Mkd: Results from Cluster Study (2017) (4)
SAT0490 IL-1 BLOCKADE IN PEDIATRIC RECURRENT PERICARDITIS: A MULTICENTRIC RETROSPECTIVE STUDY ON THE ITALIAN COHORT (2019) (4)
The macrophage migration inhibitory factor -173G/C polymorphism is not significantly associated with necrotizing enterocolitis in preterm infants. (2013) (4)
Tapering and withdrawal of tocilizumab in patients with systemic juvenile idiopathic arthritis in inactive disease: results from an alternative dosing regimen in the TENDER study (2014) (4)
Musculoskeletal manifestations of childhood cancer and differential diagnosis with juvenile idiopathic arthritis (ONCOREUM): a multicentre, cross-sectional study (2021) (4)
A54: Insulin Sensitivity Is Improved in sJIA Children With Insulin Resistance After Tocilizumab Treatment: Results From the TENDER Study (2014) (4)
FRI0540 A NOVEL AUTOINFLAMMATORY DISEASE CHARACTERIZED BY NEONATAL-ONSET CYTOPENIA WITH AUTOINFLAMMATION, RASH, AND HEMOPHAGOCYTOSIS (NOCARH) DUE TO ABERRANT CDC42 FUNCTION (2019) (4)
Improvement of Disease Activity in Patients with Colchicine-Resistant FMF, Hids/Mkd and TRAPS Assessed By Autoinflammatory Disease Activity Index (AIDAI): Results from a Randomized Phase III Trial (2017) (4)
Whole-Body MRI versus bone scintigraphy: which is the best diagnostic tool in patients with chronic recurrent multifocal osteomyelitis (CRMO)? (2015) (3)
Proceedings of the 23rd Paediatric Rheumatology European Society Congress: part two (2017) (3)
Correction: Diffuse idiopathic skeletal hyperostosis (DISH): where we are now and where to go next (2017) (3)
Dynamic Contrast-Enhanced MRI Confirms Rapid And Sustained Improvement Of Rheumatoid Arthritis Induced By Tocilizumab Treatment: An Italian Multicentre Study (2020) (3)
Efficacy and safety of tocilizumab (TCZ) in patients with systemic juvenile idiopathic arthritis (sJIA): TENDER 52-week data (2012) (3)
Case Report: Pansclerotic Morphea-Clinical Features, Differential Diagnoses and Modern Treatment Concepts (2021) (3)
Assessment of disease activity using a whole-body MRI derived radiological activity index in chronic nonbacterial osteomyelitis (2021) (3)
Reciprocal interactions between the GH/IGF-I system and cytokines (2002) (3)
Fused Omics Data Models Reveal Gut Microbiome Signatures Specific of Inactive Stage of Juvenile Idiopathic Arthritis in Pediatric Patients (2020) (3)
Catch-up growth during tocilizumab therapy for systemic juvenile idiopathic arthritis: 2-year data from a phase 3 clinical trial (2014) (3)
Effects of Retinoic Acid on TGFβ Receptor Expression in HL‐60 Cells (1990) (3)
THU0569 Pharmacokinetics and Pharmacodynamics of Canakinumab in Patients with Autoinflammatory Periodic Fever Syndromes (Colchicine Resistant FMF, HIDS/MKD and TRAPS) (2016) (3)
FRI0489 Canakinumab Improves Patient Reported Outcomes in Patients with Periodic Fever Syndromes (2016) (3)
A11: Assessment of Radiographic Progression in Patients With Polyarticular‐Course Juvenile Idiopathic Arthritis Treated With Tocilizumab: 2‐Year Data From CHERISH (2014) (3)
COVID-19 associated multisystem inflammatory syndrome in a neonate with atypical coronary artery involvement. (2022) (3)
Acute rheumatic fever prophylaxis in high-income countries: clinical observations from an Italian multicentre, retrospective study. (2020) (3)
Proceedings of the 23rd Paediatric Rheumatology European Society Congress: part two (2017) (3)
CANAKINUMAB IN SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS: REAL-LIFE DATA FROM A RETROSPECTIVE ITALIAN COHORT. (2021) (3)
[Cytokines and growth delay during chronic inflammatory diseases in children]. (1999) (2)
IgM on the surface of T cells: a novel biomarker of pediatric-onset systemic lupus erythematosus (2020) (2)
THU0503 Identification of optimal subcutaneous (SC) doses of tocilizumab in children with polyarticular-course juvenile idiopathic arthritis (PCJIA) (2017) (2)
The Italian version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) (2018) (2)
Intraarticular steroids as DMARD-sparing agents for juvenile idiopathic arthritis flares: Analysis of the Childhood Arthritis and Rheumatology Research Alliance Registry (2022) (2)
PReS-FINAL-2140: Neutropenia with Tocilizumab (TCZ) treatment is not associated with increased infection risk in patients with systemic juvenile idiopathic arthritis (SJIA) (2013) (2)
Paediatric recurrent pericarditis: Appropriateness of the standard of care and response to IL1-blockade. (2022) (2)
PReS-FINAL-2139: Tapering and withdrawal of tocilizumab in patients with systemic JIA in inactive disease: results from an alternative dosing regimen in the tender study (2013) (2)
A66: Assessment of Radiographic Progression in Patients With Systemic Juvenile Idiopathic Arthritis Treated With Tocilizumab: 2‐Year Results From the TENDER Trial (2014) (2)
Performance of a Component-Based Allergen Microarray in children with Cow's Milk and Egg Allergy (2009) (2)
Anakinra in Patients With Systemic Juvenile Idiopathic Arthritis: Long-term Safety From the Pharmachild Registry (2022) (2)
Neutralization of Interferon-gamma is efficacious in a mouse model of HLH secondary to chronic inflammation (2015) (2)
PReS-FINAL-2199: A novel mutation in the CIAS1/NLRP3 gene associated with an unusual phenotype of CAPS (2013) (2)
Kikuchi-Fujimoto disease in patient with systemic phacomatosis pigmentovascularis (2014) (2)
Chronic exposure to Interleukin-6 amplifies the response to Toll-like receptor ligands: implication on the pathogenesis of macrophage activation syndrome (2011) (2)
The Impact of Chronic Inflammation on the Growing Skeleton: Lessons from Interleukin-6 Transgenic Mice (2009) (2)
Multiple inhibitors of mitogen-induced proliferation of normal lymphocytes in juvenile chronic arthritis sera. (1990) (2)
Patterns of etanercept use in juvenile idiopathic arthritis in the Childhood Arthritis and Rheumatology Research Alliance Registry (2021) (2)
Baseline characteristics of children with juvenile dermatomyositis enrolled in the first year of the new Childhood Arthritis and Rheumatology Research Alliance registry (2022) (2)
The pathogenesis of macrophage activation syndrome (2014) (2)
Efficacy and safety of tocilizumab in patients with polyarticular juvenile idiopathic arthritis: 2-year data from the CHERISH study (2014) (2)
Trials in Progress: A Two-Cohort, Open-Label, Single-Arm Study of Emapalumab, an Anti-Interferon Gamma (IFNγ) Monoclonal Antibody, in Patients with Macrophage Activation Syndrome (MAS) in Rheumatic Diseases (2021) (2)
Morphology of the gastric mucosa, gastric secretion and serum gastrin concentration following a test meal. (1978) (2)
Pro Nerve Growth Factor and Its Receptor p75NTR Activate Inflammatory Responses in Synovial Fibroblasts: A Novel Targetable Mechanism in Arthritis (2022) (2)
Involvement of the IFN-gamma pathway in a patient with candle syndrome carrying a novel variant of PSMB8 gene (2014) (2)
Variation of serum IgG subclass concentrations with disease activity in juvenile chronic arthritis. (1989) (2)
Increased Risk of Invasive Meningococcal Disease, Pregnancy, and Confounding (2005) (2)
OP0057 EARLY TREATMENT WITH ANAKINRA IN SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS (2019) (2)
Functional Ability and Health‐Related Quality of Life in Randomized Controlled Trials of Tocilizumab in Patients With Juvenile Idiopathic Arthritis (2020) (2)
FRI0554 DNASE1L3 VARIANT IN HYPOCOMPLEMENTEMIC URTICARIAL VASCULITIS SYNDROME IDENTIFIES A DIFFERENT CLINICAL PHENOTYPE (2019) (2)
P02-016 - A novel PSMB8 mutation causing candle syndrome (2013) (2)
Chronic recurrent multifocal osteomyelitis (CRMO): typical patterns of bone involvement on MRI with particular emphasis on Whole Body MRI (WBMRI) (2015) (2)
Single center experience in Next Generation Sequencing for genetic diagnosis of Autoinflammatory Disorders (AIDs) (2015) (2)
Clinical report and predictors of sequelae of 319 cases of pediatric bacterial osteomyelitis (2022) (2)
The pediatric glucocorticoid toxicity index. (2022) (2)
Deregulation of IL-1β axis in peripheral blood mononuclear cells from patients with Chronic Recurrent Multifocal Osteomyelitis (2011) (1)
AB1059 A RANDOMIZED, PLACEBO-CONTROLLED STUDY OF ANAKINRA IN PATIENTS WITH STILL´S DISEASE (2020) (1)
Macrophage Activation Syndrome in Rheumatic Diseases (MAS-HLH) (2018) (1)
THU0517 THE LONGITUDINAL EUROFEVER PROJECT: AN UPDATE ON ENROLLMENT (2019) (1)
AB1115 A novel mutation in the CIAS1/NLRP3 gene associated with an unexpected phenotype of caps (2013) (1)
Tocilizumab for massive refractory pleural effusion in an adolescent with systemic lupus erythematosus (2021) (1)
Cronic non-bacterial osteomyelitis (CNO) in a cohort of pediatric patients: clinical, biological and radiological response to treatment with Anakinra (2015) (1)
THU0516 LONG-TERM SAFETY OF SUBCUTANEOUS TOCILIZUMAB ADMINISTRATION IN SYSTEMIC AND POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS (2019) (1)
Measurement of Cytokines in Synovial Fluid (2001) (1)
SAT0470 Efficacy of Biologic Treatments in Juvenile Idiopathic Arthritis with a Polyarticular Course: An Indirect Comparison (2013) (1)
Functional and prognostic significance of the-173 polymorphism of the macrophage migration inhibitory factor (MIF) gene in systemic JIA. (2002) (1)
Correction to: The Italian version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) (2018) (1)
PReS-FINAL-2180: Efficacy and safety of tocilizumab (TCZ) in patients with polyarticular-course juvenile idiopathic arthritis (pcJIA): 2-year data from CHERISH (2013) (1)
OP0254 CANAKINUMAB IMPROVES PATIENT-REPORTED OUTCOMES IN PATIENTS WITH RECURRENT FEVER SYNDROMES: RESULTS FROM A PHASE 3 TRIAL (CLUSTER) (2019) (1)
OP0063 Canakinumab treatment in patients with colchicine-resistant FMF (CRFMF), HIDS/MKD and traps: efficacy in the 16 weeks randomised controlled phase and maintenance of disease control and safety at week 40 (2017) (1)
systemic-onset juvenile chronic arthritis erythropoietin production in the anemia associated with Defective iron supply for erythropoiesis and adequate endogenous (2009) (1)
Social determinants of health influence disease activity and functional disability in Polyarticular Juvenile Idiopathic Arthritis (2022) (1)
SAT0438 Catch-Up Growth During Tocilizumab Therapy for Systemic Juvenile Idiopathic Arthritis: 2-Year Data from a Phase 3 Clinical Trial (2013) (1)
O53. Efficacy and Safety of Tocilizumab in Polyarticular-Course Juvenile Idiopathic Arthritis: 2 Year Data from Cherish (2014) (1)
HL-60 cells : possible TGF-beta 1-mediated autocrine inhibition expression and TGF-beta 1 protein production in retinoic acid-treated Induction of transforming growth factor-beta 1 ( TGF-beta 1 ) , receptor (2003) (1)
PW02-007 - The Eurofever registry: 3 years of enrollment (2013) (1)
SAT0483 Tapering and Withdrawal of Tocilizumab in Patients with Systemic Juvenile Idiopathic Arthritis in Inactive Disease: Results from an Alternative Dosing Regimen in the Tender Study (2015) (1)
OP0193 EFFICACY AND SAFETY OF EMAPALUMAB, AN ANTI-INTERFERON GAMMA MONOCLONAL ANTIBODY, IN PATIENTS WITH MACROPHAGE ACTIVATION SYNDROME (MAS) IN SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS (sJIA) WHO HAD FAILED HIGH-DOSE GLUCOCORTICOIDS (2022) (1)
THU0570 Long-term efficacy and safety of canakinumab in patients with colchicine-resistant fmf (CRFMF), traps and hids/mkd: results from the pivotal phase 3 cluster trial (2018) (1)
P03-012 - A P268S NOD2 mutation in one Blau patient (2013) (1)
Efficacy and safety of emapalumab in macrophage activation syndrome (2022) (1)
THU0508 Safety and Efficacy of Tocilizumab in Patients with Systemic Juvenile Idiopathic Arthritis: 5-Year Data from Tender, A Phase 3 Clinical Trial (2015) (1)
Correction: Efficacy and safety of non-pharmacological and non-biological pharmacological treatment: a systematic literature review informing the 2016 update of the ASAS/EULAR recommendations for the management of axial spondyloarthritis (2017) (1)
PReS-FINAL-2238: PAPA (pyogenic arthritis, pyoderma gangrenosum and acne) syndrome: results from the Eurofever registry (2013) (1)
OP0255 MICROBIOTA TRANSPLANT TO CONTROL INFLAMMATION IN A NLRC4-RELATED DISEASE PATIENT WITH RECURRENT HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS (HLH) (2019) (1)
In Vitro Isolation of Human Cytotoxic Clones Specific for Autologous Leukemic Blasts (1994) (1)
Assessment of Disease Activity Using a Whole-body MRI Derived Radiological Activity Index in Chronic Nonbacterial Osteomyelitis (2021) (1)
Secondary thrombocytosis [4] (1993) (1)
[Changes in the production of IgM in response to pokeweed mitogen in juvenile rheumatoid arthritis. Correlations with disease activity]. (1990) (1)
289. Assessment of Radiographic Progression in Patients with Systemic Juvenile Idiopathic Arthritis Treated with Tocilizumab: 2-Year Results from the Tender Trial (2014) (1)
PReS-FINAL-2159: Tocilizumab (TCZ) dosing in juvenile idiopathic arthritis (JIA): optimising for different JIA type and body weight patients (2013) (1)
OP0062 The Addition of One or More Biologics to Methotrexate in Children with Juvenile Idiopathic Arthritis Increases the Incidence of Infections and Serious Adverse Events. The 5882 Pharmachild Cohort (2015) (1)
BHPR research: qualitative1. Complex reasoning determines patients’ perception of outcome following foot surgery in rheumatoid arhtritis (2012) (1)
Interferon gamma (IFNg) drives disease in the TLR9-mediated cytokine storm syndrome in mice (2015) (1)
The Eurofever Registry for autoinflammatory diseases: results of the first 15 months of enrolment (2011) (1)
Subject Index Vol. 72, Suppl. 1, 2009 (2009) (1)
AB0932 PREDICTORS OF FLARE FOLLOWING ETANERCEPT WITHDRAWAL IN PATIENTS WITH RHEUMATOID FACTOR NEGATIVE JUVENILE IDIOPATHIC ARTHRITIS DURING 48 MONTHS OF FOLLOW-UP (2019) (1)
Post-Transplant Outcomes of Children with Primary Hemophagocytic Lymphohistiocytosis Given Emapalumab to Control Disease (2019) (1)
A controlled trial of intra-articular corticosteroids with or without methotrexate in oligoarticular juvenile idiopathic arthritis (2014) (1)
Correction: Abatacept in combination with methotrexate in Japanese biologic-naive patients with active rheumatoid arthritis: a randomised placebo-controlled phase IV study (2019) (1)
Juvenile idiopathic arthritis: will etanercept be an improvement over current therapies? (2000) (1)
P090 Protocol for the two-cohort, open-label, single-arm EMERALD study of emapalumab, an anti-interferon gamma monoclonal antibody, in patients with macrophage activation syndrome in rheumatic diseases (2023) (0)
Use of the Auto-inflammatory Disease activity Index to Monitor Disease Activity in Patients with crFMF, MKD, and TRAPS Treated with Canakinumab. (2022) (0)
THU0527 RISK SCORE OF MACROPHAGE ACTIVATION SYNDROME IN PATIENTS WITH SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS (2019) (0)
OP0059 PERIARTICULAR GLUCOCORTICOID INJECTIONS: DELINEATING THEIR USE IN JUVENILE IDIOPATHIC ARTHRITIS (2019) (0)
Impact of chronic inflammation on bone during childhood (2006) (0)
170 Safety and efficacy of subcutaneous tocilizumab in patients with systemic and polyarticular juvenile idiopathic arthritis (2019) (0)
Variation ofserum IgGsubclass concentrations with disease activity injuvenile chronic arthritis (1989) (0)
THU0550 MYCOPHENOLATE MOFETIL (MMF) IN DEFINED AND UNDEFINED INTERFERONOPATHIES (2019) (0)
What should the intelligent clinician ask of the immunology laboratory (1991) (0)
PReS13-SPK-1590: Relevance of cytokine in pediatric inflammatory disease (2013) (0)
D.P.3.10 Partial caveolin 3 deficiency in acquired rippling muscle disease (2008) (0)
ANTIBODIES TO HISTONES IN AUTOIMMUNE HEPATITIS OF CHILDHOOD (1997) (0)
FRI0539 WNT6 MUTATION CAUSES AN EARLY ONSET GRANULOMATOSUS INTESTINAL DISEASE WITH RECURRENT HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS (HLH) (2019) (0)
Muscle and bone in muscular dystrophy: Why not? (2013) (0)
ORAL PRESENTATION OF ABSTRACTS PAEDIATRIC AND ADOLESCENT ORAL ABSTRACTS (2016) (0)
Post-Transplant Outcomes of Children with Primary Hemophagocytic Lymphohistiocytosis Treated with Emapalumab (2021) (0)
AB0185 INTERFERON-Γ AMPLIFIES IMMUNE RESPONSE MEDIATED BY TYPE I INTERFERONS IN PAEDIATRIC SYSTEMIC LUPUS ERYTHEMATOSUS AND CORRELATES WITH DISEASE ACTIVITY (2019) (0)
AB1069 HYPERZINCAEMIA AND HYPERCALPROTECTINEMIA SYNDROME: MORE THAN JUST AUTOINFLAMMATION? (2019) (0)
79 Mannose Binding Lectin |[lpar]|MBL|[rpar]| Yy Genotype is Associated with An Increased Risk of Necrotizing Enterocolitis|[lpar]|NEC|[rpar]| in Preterm Neonates in NICU (2010) (0)
SAT0511 CANAKINUMAB IN SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS: CLINICAL INACTIVE DISEASE RATE AND SAFETY IN ITALIAN PATIENTS (2019) (0)
Inhibition of c-Src reduces IL-6 expression in vivo and in vitro (2009) (0)
PCS Programme (2011) (0)
Oral Session II‐A (OII‐A) (2011) (0)
chronic arthritis . disease activity in juvenile subclass concentrations with Variation of serum IgG (2004) (0)
FRI0542 CLINICAL PRESENTATION, GENETIC ANALYSIS AND IFN-SCORE IN PATIENTS WITH UNDEFINED INTERFERONOPATHIES (2019) (0)
The Journal of Rheumatology Remission while Taking Medication negative Juvenile Idiopathic Arthritis Who Reached − Rheumatoid Factor Predictors of Flare Following Etanercept Withdrawal in Patients with (2018) (0)
AB0062 P75NTR IN THE MODULATION OF INFLAMMATORY RESPONSE MEDIATED BY SYNOVIAL FIBROBLASTS (2019) (0)
Systemic and local determinants contribute to the bone phenotype in duchenne muscular dystrophy (2011) (0)
SAT0497 CLINICAL PICTURE OF 7 PAPA PATIENTS FOLLOWED IN A SINGLE PEDIATRIC RHEUMATOLOGIC CENTER (2019) (0)
409 Decreased fibrinolytic activity in active juvenile rheumatoid arthritis (1988) (0)
FC-OPG prevents IL-6 dependent bone loss and impaired skeletal growth in IL-6 transgenic mice. implications for therapy in juvenile chronic inflammatory diseases (2010) (0)
Clinical Connections (2019) (0)
Safety of Emapalumab in Children with Primary Hemophagocytic Lymphohistiocytosis: Results of the Primary Analysis of the Pivotal Phase 2/3 Study (2020) (0)
In vivo relevance of the interplay between IL-6 and C-SRC in the regulation of osteoblast function. Involvement of the IGF-1/IGFBPS axis (2010) (0)
The Eurofever project: an update on the longitudinal stage (2017) (0)
Anti-interferon-γ Therapy for Cytokine Storm Syndromes (2019) (0)
TENDER Trial 2-Year Outcomes Show Long-Term Benefits of Tocilizumab in sJIA (2011) (0)
A171: Tocilizumab Dosing in Juvenile Idiopathic Arthritis: Optimizing for Different Juvenile Idiopathic Arthritis Type and Patient Body Weight (2014) (0)
277. Growth During Tocilizumab Therapy in Patients with Polyarticular-Course Juvenile Idiopathic Arthritis: 2-Year Data from the Phase III Cherish Trial (2015) (0)
Antagonist hIL-6-Transgenic Mice with a hIL-6 Receptor ( hIL-6 ) Achieved by Immunization of In Vivo Neutralization of Human IL-6 (2001) (0)
Macrophage migration inhibitory factor -173 G/C polymorphism is not signifi cantly associated with necrotizing enterocolitis in preterm neonates in NICU (2013) (0)
chronic arthritis . Decreased fibrinolytic activity in juvenile (0)
Macrophage Migration Inhibitory Factor -173 G/C Polymorphism is Not Associated with An Increased Risk of Necrotizing Enterocolitis in Preterm Neonates in NICU (2011) (0)
OP0164 LONG-TERM SAFETY OF ANAKINRA IN PATIENTS WITH SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS FROM THE PHARMACHILD REGISTRY (2021) (0)
THU0530 IDIOPATHIC RECURRENT PERICARDITIS: CLINICAL FINDINGS AND TREATMENT APPROACH (2019) (0)
OP0258 LESSON FROM EUROFEVER REGISTRY AFTER THE FIRST TEN YEARS OF ENROLLMENT (2019) (0)
06. Identification of optimal subcutaneous doses of tocilizumab in children with polyarticular-course juvenile idiopathic arthritis (2017) (0)
New experimental therapy to rescue impaired skeletal growth and bone loss in a mouse model of IL-6 dependent juvenile inflammatory diseases (2011) (0)
Forum in Bone and Mineral Research 5th Meeting Saint Vincent (Italy) 22–23 November 2007 (2008) (0)
Subject Index Vol. 58, Suppl. 1, 2002 (2002) (0)
AB0940 OBESITY AND NUMBER OF ACTIVE JOINTS AT TUMOR NECROSIS FACTOR-INHIBITOR START ARE ASSOCIATED WITH SHORTER REMISSION DURATION AFTER WITHDRAWAL IN PATIENTS WITH JUVENILE IDIOPATHIC ARTHRITIS: PRELIMINARY RESULTS FROM A MONOCENTRIC COHORT (2019) (0)
Virus and rheumatic diseases (2007) (0)
Sensitivity Analysis of Overall Response Rate (ORR) with Emapalumab in Children with Primary Hemophagocytic Lymphohistiocytosis (HLH) (2020) (0)
Mechanisms underlying low bone density in muscular dystrophy (2009) (0)
FRI0549 SARILUMAB, A HUMAN MONOCLONAL ANTIBODY TO THE INTERLEUKIN-6 (IL-6) RECEPTOR, IN POLYARTICULAR-COURSE JUVENILE IDIOPATHIC ARTHRITIS (PCJIA): A 12-WEEK MULTINATIONAL OPEN-LABEL DOSE-FINDING STUDY (2019) (0)
THE EUROFEVER REGISTRY FOR AUTOINFLAMMATORY DISEASE: UPDATE ON ENROLLMENT AFTER 2 YEARS (2013) (0)
AB1062 INTER-LABORATORY COMPARISON OF TYPE I INTERFERON SIGNATURE ANALYSES: PAVING THE WAY TO SHARE RECOMMENDATIONS. (2019) (0)
AB0989 PATIENTS’ AND CAREGIVERS’ ASSESSMENT OF A DEDICATED OUTPATIENT SERVICE FOR INTRAARTICULAR GLUCOCORTICOID INJECTIONS IN JUVENILE IDIOPATHIC ARTHRITIS (2019) (0)
Regulatory loops involving IGFBP5 account for a fine tuning regulation of osteoblast and osteoclast activity in the context of the IL-6 pathway (2011) (0)
THU0513 WHOLE BLOOD CELLS FROM PATIENTS WITH SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS (SJIA) IN CLINICAL INACTIVE DISEASE DISPLAY A DYSREGULATED RESPONSE TO TLR-4 STIMULATION (2019) (0)
FRI0572 DISABILITY AND HEALTH-RELATED QUALITY OF LIFE OUTCOMES IN PATIENTS WITH SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS TREATED WITH TOCILIZUMAB IN A PHASE 3 RANDOMIZED CONTROLLED TRIAL (2019) (0)
Eosinophilic Esophagitis and IgE Mediated Allergy in Children: Detection of Specific IgE by a Microarray-Based assay (MBa) (2011) (0)
THU0507 TYPE I INTERFERON SCORE AND INTERFERON INDUCED MEDIATORS CXCL10 AND NEOPTERIN ARE CORRELATED WITH DISEASE ACTIVITY IN JUVENILE DERMATOMYOSITIS (2019) (0)
Disclosure statement: The authors have declared no conflicts of interest. 277. CHRONIC FOOT PROBLEMS IN PEOPLE WITH GOUT: AN OBSERVATIONAL STUDY IN PRIMARY CARE (2014) (0)
ifnγ Drives Disease In Tlr9-mediated Secondary Hemophagocytic Lymphohistiocytosis (shlh) In Mice. Rationale For A New Therapeutic Target In Hlh Secondary To Infection In Humans (2015) (0)
BTT_A_209873 13..21 (2020) (0)
Interleukin (IL)-1 Blocking Compounds and Their Use in Autoinflammatory Diseases (2019) (0)
AB1404-HPR JIA TEAMWORK FOR IMPROVING PATIENTS’ ACCEPTANCE OF INTRAARTICULAR GLUCOCORTICOID INJECTIONS IN LOCAL ANESTHESIA IN OUTPATIENT DEDICATED SERVICE (2019) (0)
Tolvaptan in Autosomal Dominant Polycystic Kidney Disease (2013) (0)
A13 Macrophage migration inhibitory factor-173 G/C polymorphism is not significantly associated with an increased risk of necrotising enterocolitis in preterm neonates in NICU (2012) (0)
The pathogenesis of macrophage activation syndrome (2014) (0)
O43 5-Year Data from Tender, a Phase III Clinical Trial: Safety and Efficacy of Tocilizumab in Patients with Systemic Juvenile Idiopathic Arthritis (2016) (0)
PP11. Assessment of radiographic progression in patients with systemic juvenile idiopathic arthritis treated with tocilizumab: 2-year data from tender (2015) (0)
Correction: Idiopathic inflammatory myopathies: narrative review of unmet needs in clinical practice guidelines (2019) (0)
Correction: Impact of autoimmune rheumatic diseases on birth outcomes: a population-based study (2019) (0)
Correction: Low rates of radiographic progression of structural joint damage over 2 years of baricitinib treatment in patients with rheumatoid arthritis (2019) (0)
How to monitor the progression of the arthritic process (2003) (0)
Correction: Drug-specific risk and characteristics of lupus and vasculitis-like events in patients with rheumatoid arthritis treated with TNFi: results from BSRBR-RA (2017) (0)
Correction: ACPA and RF as predictors of sustained clinical remission in patients with rheumatoid arthritis: data from the Ontario Best practices Research Initiative (OBRI) (2019) (0)
Correction: Secukinumab in the treatment of psoriatic arthritis: efficacy and safety results through 3 years from the year 1 extension of the randomised phase III FUTURE 1 trial (2018) (0)
Correction: Imaging of diffuse idiopathic skeletal hyperostosis (DISH) (2020) (0)
Correction: Comparative effectiveness of subcutaneous tocilizumab versus intravenous tocilizumab in a pan-European collaboration of registries (2019) (0)
2017 Thank you to our reviewers (2018) (0)
Correction: Which patients presenting with arthralgia eventually develop rheumatoid arthritis? (2018) (0)
Correction: Opportunities and challenges for real-world studies on chronic inflammatory joint diseases through data enrichment and collaboration between national registers: the Nordic example (2018) (0)
Correction: Atlas for the OMERACT thumb base osteoarthritis MRI scoring system (TOMS) (2018) (0)
Correction: ProNGF-p75NTR axis plays a proinflammatory role in inflamed joints: a novel pathogenic mechanism in chronic arthritis (2017) (0)
Correction: 4-year results from the RAPID-PsA phase 3 randomised placebo-controlled trial of certolizumab pegol in psoriatic arthritis (2018) (0)
Correction: Ixekizumab is efficacious when used alone or when added to conventional synthetic disease-modifying antirheumatic drugs (cDMARDs) in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor inhibitors (2019) (0)
Correction: Development of generic core competences of health professionals in rheumatology: a systematic literature review informing the 2018 EULAR recommendations (2019) (0)
Correction: Translation of clinical problems in osteoarthritis into pathophysiological research goals (2016) (0)
Low levels of the nerve growth factor receptor TrkA in JIA: a possible defect in a novel anti-inflammatory mechanism (2011) (0)
P01-050 – Anakinra in systemic JIA: single center experience (2013) (0)
Canakinumab improves patient-reported outcomes in children and adults with autoinflammatory recurrent fever syndromes: results from the CLUSTER trial. (2021) (0)
[Cytokines: present and future therapeutic applications]. (1989) (0)
[Results of treatment with a new antacid (Rowagastrit) in gastropathies]. (1969) (0)
POS0339 POINTS TO CONSIDER AT THE EARLIEST STAGES OF THE DIAGNOSIS AND MANAGEMENT OF HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS/MACROPHAGE ACTIVATION SYNDROME (HLH/MAS) (2022) (0)
PW02-009 - PAPA syndrome: results from the Euroefever registry (2013) (0)
Acute rheumatic fever with chorea (2012) (0)
[Multidisciplinary approach]. (2009) (0)
SAT0386 Adjudication of infections from the pharmacovigilance in juvenile idiopathic arthritis patients (PHARMACHILD) treated with biologic agents and/or methotrexate: update on results with a focus on opportunistic infections (2018) (0)
Unifocal and multifocal chronic non-bacterial osteomyelitis (CNO) in children (2011) (0)
[Hemato-tissue eosinophilia in a case of ulcerative rectocolitis]. (1976) (0)
Low levels of the nerve growth factor receptor TrkA in JIA: a possible defect in a novel anti-inflammatory mechanism (2011) (0)
PReS-FINAL-2337: The eurofever registry: 3 years of enrollment (2013) (0)
POS1307 HEMATOLOGICAL MANIFESTATIONS IN THE PRESENCE OF ANTIPHOSPHOLIPID ANTIBODIES IN A PEDIATRIC COHORT (2022) (0)
PReS-FINAL-2186: Monoallelic mutations of familial hlh-related genes associated to macrophage activation syndrome (2013) (0)
Childhood-Onset Lupus Nephritis in the Childhood Arthritis and Rheumatology Research Alliance Registry: Short-Term Kidney Status and Variation in Care. (2022) (0)
A rare cause of multiple airways narrowing in a 15-year-old girl (2020) (0)
PReS-FINAL-2142: Predictors of persistent remission following etanercept (ETN) withdrawal in patients with juvenile idiopathic arthritis (JIA) (2013) (0)
PW02-037 - The Eurofever cohort of 136 patients with CAPS (2013) (0)
OR6-005 – Cystine crystals activate inflammasomes (2013) (0)
Characterization of AR-CGD female patient with a novel homozygous deletion in CYBC1 gene presenting with unusual clinical phenotype. (2023) (0)
S10.3 Genetical and phenotypical findings of childhood-onset systemic lupus erythematosus (2022) (0)
PReS-FINAL-2202: A novel PSMB8 mutation associated with CANDLE syndrome (2013) (0)
[The feeding of heart disease patients]. (1968) (0)
Response to: ‘Correspondence on ‘Long-term efficacy and safety of canakinumab in patients with colchicine-resistant familial Mediterranean fever: results from the randomised phase III CLUSTER trial’’ by Satis et al (2020) (0)
PO.2.31 Different patterns of longitudinal changes in antinuclear antibodies titres in children with systemic lupus erythematosus (2022) (0)
Inflammatory Cytokine response in a cohort of patients carrying novel NLRP12 variants (2015) (0)
OP0103 Identification of optimal subcutaneous doses of tocilizumab in children with systemic juvenile idiopathic arthritis (2018) (0)
PReS-FINAL-2096: Herpes virus infections in patients with juvenile idiopathic arthritis (JIA) treated with etanercept (2013) (0)
Anti-interferon-γ Therapy for Cytokine Storm Syndromes (2019) (0)
PReS-FINAL-2201: A P268S NOD mutation in one Blau patient (2013) (0)
[On the clinical action of a new derivative of maritime squill (proscillaridinA)]. (1967) (0)
PW02-022 - Recurrent fever syndromes: multiple gene mutations (2013) (0)
OP0008 Single Center Experience in Next Generation Sequencing for Genetic Diagnosis of Autoinflammatory Disorders (AIDS) (2015) (0)
OP0134 Increased Muscle Interferon-γ Expression Levels in Juvenile Dermatomyositis (2015) (0)
Targeting interleukin-6 in pediatric rheumatic diseases (2009) (0)
Prevalence of monogenic autoinflammatory diseases among Pediatric Rheumatology centers: the Eurofever PReS/PRINTO survey (2008) (0)
P02-031 - Phenotype of V198M and Q703K NLRP3 variants (2013) (0)
OP0272 LONG-TERM EFFICACY AND SAFETY OF CANAKINUMAB IN PATIENTS WITH COLCHICINE-RESISTANT FAMILIAL MEDITERRANEAN FEVER: RESULTS FROM THE RANDOMISED PHASE 3 CLUSTER TRIAL (2020) (0)
PReS13-SPK-1590: Relevance of cytokine in pediatric inflammatory disease (2013) (0)
Reumatologia (2021) (0)
Auricular leishmaniasis in a child successfully treated with intralesional amphotericin B (2022) (0)
[Inosine in the therapy of heart diseases]. (1960) (0)
203 Low Mannose Binding Lectin (MBL) Serum Levels And Hospital Acquired Infections (HAI) in Neonates in a Neonatal Intensive Care Unit (NICU) (2004) (0)
PReS-FINAL-2359: Renal involvement in hypocomplementemic urticarial vasculitis syndrome (huvs): report of 3 paediatric cases (2013) (0)
PO.6.141 Efficacy of mycophenolate mofetil (MMF) in pediatric patients with defined and undefined type I interferonopathies (2022) (0)
It is about time: the first validated biomarker for early diagnosis of sJIA. (2021) (0)
Long-term efficacy and safety of canakinumab in patients with mevalonate kinase deficiency: results from the randomised Phase 3 CLUSTER trial. (2021) (0)
SAT0325 Chronic Recurrent Multifocal Osteomyelitis (CRMO): Typical Patterns of Bone Involvement on MRI with Particular Emphasis on Whole Body MRI (WBMRI) (2015) (0)
Clinical presentation and cytokine production abnormalities in a cohort of patients carrying NLRP12 gene variants (2014) (0)
FRI0323 Cronic Non-Bacterial Osteomyelitis (CNO) in a Cohort of Pediatric Patients: Clinical, Biological and Radiological Response to Treatment with Anakinra (2015) (0)
OP0175 The eurofever registry for autoinflammatory disease: Update on enrollment after 2 years (2013) (0)
PReS-FINAL-2070: Efficacy of biologic treatments in juvenile idiopathic arthritis with a polyarticular course: an indirect comparison (2013) (0)
[Gastroscopic findings in habitual heavy drinkers]. (1974) (0)
A heterozygous RAB27A mutation causes delayed cytolytic granule polarization and hemophagocytic lymphohistiocytosis in 2 unrelated teenagers (2016) (0)
PReS-FINAL-2134: Assessment of radiographic progression in patients (pts) with systemic juvenile idiopathic arthritis (sjia) treated with tocilizumab (TCZ): 2-year results from the tender trial (2013) (0)
Case Report: Interindividual variability and possible role of heterozygous variants in a family with deficiency of adenosine deaminase 2: are all heterozygous born equals? (2023) (0)
Somatic and Abdominal Acupuncture for Pain Treatment in Adolescent Complex Regional Pain Syndrome (CRPS) of the Upper Limb: A Case Report (2021) (0)
[Inosine in liver diseases]. (1962) (0)
PReS-FINAL-2183: IL-6 amplifies toll like receptor mediated cytokine and chemokine production: implications for the pathogenesis of rheumatic inflammatory diseases (2013) (0)
[Adolescence and modern mass media]. (1978) (0)
PReS-FINAL-2200: Phenotype of V198M and Q703K NLRP3 variants (2013) (0)
[Contribution to anti-inflammatory therapy: results obtained with indomethacin]. (1967) (0)
P02-032 - CAPS: a novel mutation and an unusual phenotype (2013) (0)
Proceedings of the 23rd Paediatric Rheumatology European Society Congress: part three (2017) (0)
Incidence and predictors of pericardial effusion following surgical closure of atrial septal defect in children: A single center experience (2022) (0)
[Development of histological lesions in ulcerative rectocolitis after medical treatment]. (1971) (0)
The role of steroid injection in joints and tendon sheaths in JIA in the biologic era (2014) (0)
[Alpha 1 fetal proteins in chronic hepatitis]. (1974) (0)
Sjogren Syndrome, Raynaud’s Phenomenon, Overlap Syndromes (2012) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Fabrizio De Benedetti?

Fabrizio De Benedetti is affiliated with the following schools: